Study of the Performance of the GLUCUBE System in Patients With Type 2 Diabetes

NCT ID: NCT07075796

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-02

Study Completion Date

2025-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, single center, open label clinical investigation. The primary objective of the study is to evaluate the performance of GLUCUBE in patients with diabetes type 2 and how the accuracy of the system improves as the time of use by the patient increases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Current methods of measuring blood glucose, glucometers, although minimally invasive, can be painful as they require puncturing the fingertip with a prick device and drawing a drop of blood, which is applied to a disposable test strip. This minimal invasiveness can cause discomfort and discourage the user from testing their blood glucose levels as frequently as necessary, leading to poor glycemic control. Due to the non-invasive nature of the GLUCUBE system, it provides glucose level information safely and painlessly, avoiding any discomfort to the user. It is low cost as it uses commonly used electronic components and does not require test strips or other consumables that would increase the ongoing cost of the device. The performance of the GLUCUBE system has already been evaluated in comparison to the standard glucometer (Ascensia Contour®Next) in adult patients with and without diabetes. The primary objective of this clinical investigation is to evaluate the performance of GLUCUBE in patients with diabetes type 2 and how the accuracy of the system improves as the time of use by the patient increases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open-Label

GLUCUBE system performance in the monitoring and measurement of the blood glucose compared to the standard glucometer (blood capillary glucometer - Bayer Contour®Next).

Group Type OTHER

GLUCUBE system

Intervention Type DEVICE

A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLUCUBE system

A non-invasive system to monitor and measure the blood glucose compared to the standard glucometer in a group subjects

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be ≥ 18 years of age.
* Diagnosed with type 2 diabetes mellitus.
* Have a smartphone with an internet connection that allows the installation of the GLUCUBE APP.
* Be able to use the GLUCUBE system autonomously, in the opinion of the researcher.
* Have signed the informed consent.

Exclusion Criteria

* The patient is currently participating in another clinical investigation or has participated in another clinical investigation in the last 30 days prior to the start of this study.
* Pregnant or breast-feeding women and those subjects who plan pregnancy during the clinical investigation follow-up period.
* Presence of other anatomical or comorbid conditions, or other medical, social or psychological conditions that, in the opinion of the investigator, could limit the subject's ability to participate in the clinical investigation or to comply with the follow-up requirements, or affect the scientific soundness of the clinical investigation results.
* Patients with any active and/or infectious acute illness.
* Patients who have a condition that affects blood circulation in the fingers of the hand, such as Raynaud's phenomenon.
* Any medical condition that, in the opinion of the investigator, will increase the risk of hyperglycemic and hypoglycemic events: seizures, heart disease, unconscious hypoglycemia, etc.
* Patients with an inability to maintain hand stability during measurement or with progressive nervous system disease affecting movement (Parkinson's disease, moderate-severe essential tremor, and other diseases with involuntary movements).
* Patients suffering from calluses, malformations, or open wounds with bandages on their hands.
* Patients with nail polish or any type of false nail.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

iGluco

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centro de Especialidades Virgen de los Reyes. Hospital Universitario Virgen del Rocío

Seville, Seville, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-NIGM-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study for Patients With Type 2 Diabetes
NCT01027871 COMPLETED PHASE2